Lifecore Biomedical to Participate at DCAT Week 2026

CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City.

GlobeNewsWire • Feb 17, 2026

Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Settles

Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities fraud class action settles.

GlobeNewsWire • Jan 30, 2026

HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders.

PRNewsWire • Jan 29, 2026

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore's Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.

GlobeNewsWire • Jan 16, 2026

Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders. If you currently own Lifecore stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about.

Business Wire • Jan 15, 2026

Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Settles

Philadelphia, Pennsylvania--(Newsfile Corp. - January 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities fraud class action has reached a settlement. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Newsfile Corp • Jan 13, 2026

Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement

Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.

Newsfile Corp • Jan 8, 2026

Lifecore Biomedical: The Turnaround Is Just Getting Started

Lifecore Biomedical (LFCR) has completed its turnaround, emerging as a pure-play US-based CDMO with a cleaned-up balance sheet and high operational leverage. LFCR's new capacity is underutilized but already contracted, with management guiding revenues to rise from $128M to $178–205M and EBITDA margins to expand from 15% to over 25%. Alcon's take-or-pay contract and a major commercial site transfer underpin the revenue ramp, while macro tailwinds and supply chain onshoring boost demand.

Seeking Alpha • Jan 1, 2026

Lifecore Biomedical to be Added to Nasdaq Biotech Index

CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company's stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore's inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025.

GlobeNewsWire • Dec 18, 2025

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product

GlobeNewsWire • Dec 17, 2025